Our database has undergone a major update! We expect some minor teething issues, please let us know by using the Report an issue button at the top of every page if you spot anything that doesn't work.

• 1/5 BADBIR will be attending the BAD meeting on June 30th this year, for the full three days.
• 2/5 Recruitment for patients commencing Sotyktu (deucravicitinib) will end on 20th of May 2026. Please ensure that all potential participants have provided consent to join BADBIR before this date.
• 3/5 Read more: Changes to conventional cohort eligibility criteria
• 4/5 Our new 2025 Annual Update is available to read here
• 5/5 Patients diagnosed with Generalised Pustular Psoriasis are eligible on Spevigo (spesolimab) or conventional treatment

Find out more on our website.